Standard BioTools

LAB

Market cap $493M

Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, customers commend scale, high consistency, and easy sample to insights workflow Launch follows Illumina's announcement of agreement to acquire SomaLogic SAN DIEGO , Sept. 3, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of Illumina Protein Prep, an assay introducing superior performance for next-generation sequencing (NGS) based proteomics discovery at scale.

Standard BioTools (LAB) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.08 per share a year ago.

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET.

PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan's strategic position in the high-impact biobank segment and its increasing role in leading global health initiatives SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that the Precision Health Research, Singapore (PRECISE-SG100K) selected the SomaScan™ 11K Assay to run 100,000 plasma samples from the PRECISE-SG100K biobank following a comprehensive evaluation of competitive proteomics offerings.

SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.

Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO , June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties. "The acquisition of SomaLogic will enhance Illumina's presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024.

Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash   Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business    Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even    Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced the strategic sale of SomaLogic to Illumina, Inc. (NASDAQ: ILMN) (“Illumina”), including SomaScan® Assay Services, Authorized Sites and KREX™ for an upfront payment of $350 million in cash at closing and up to $75 million in cash in near-term milestone payments, for aggregate cash consideration of up to $425 million, plus specified sales royalties on SOMAmer-based next-generation sequencing (NGS) library preparation kits (Illumina Protein Prep).

Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development

Standard BioTools Inc. (NASDAQ:LAB ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants John Graziano - VP of IR Michael Egholm - President & CEO Alex Kim - CFO Conference Call Participants Kyle Boucher - TD Cowen Matt Stanton - Jefferies Paul Knight - KeyBanc Operator Good day and welcome to the Standard BioTools, Inc., First Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.

Standard BioTools (LAB) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.23 per share a year ago.